About

The KPV peptide is a short synthetic sequence composed of the amino acids lysine (K), proline (P) and valine (V). It has been investigated for its anti-inflammatory properties in various preclinical models. The 5 mg formulation is typically supplied as a dry powder or lyophilized vial, ready to be reconstituted with sterile water or buffer before use. This dosage form allows researchers to adjust the concentration according to their experimental protocols and ensures accurate dosing when studying cellular responses or animal models.



Key details of the KPV Peptide 5 mg product include its purity level, usually greater than 95 % as confirmed by high performance liquid chromatography (HPLC). The peptide is synthesized using solid-phase techniques that provide a defined sequence with minimal impurities. It is commonly packaged in a single-use vial to avoid cross-contamination and preserve stability during storage at –20 °C or below.



The Certificate of Analysis for each batch of KPV Peptide 5 mg lists critical quality attributes such as:




Molecular weight confirmation by mass spectrometry


Purity assessment via HPLC retention time and peak area


Residual solvents measured against regulatory limits


Endotoxin level, typically below 0.1 EU/mg to ensure suitability for in vitro or in vivo applications


Sterility testing confirming absence of bacterial or fungal growth



These data provide confidence that the peptide meets rigorous standards required for research purposes and potential therapeutic development.

Intended use of KPV Peptide 5 mg is primarily within scientific investigation rather than clinical treatment. Researchers employ it to study its modulatory effects on immune cells, particularly macrophages and neutrophils, where it can attenuate pro-inflammatory cytokine release such as tumor necrosis factor alpha and interleukin-6. In animal studies, KPV has been used to reduce inflammation in models of arthritis, colitis, or respiratory distress, often by intraperitoneal injection or topical application depending on the disease model.



In vitro, the peptide is typically dissolved to a working concentration ranging from 1 µM to 100 µM in cell culture media. Dose-response curves help identify optimal concentrations that suppress inflammatory markers without cytotoxicity. For in vivo studies, dosing regimens are tailored to the animal species; for example, mice might receive daily intraperitoneal injections of 0.5–1 mg/kg, while larger animals require adjustments based on body weight and pharmacokinetic data.



Because KPV is a small peptide, it can be chemically modified to enhance stability or delivery. Researchers sometimes conjugate it with polyethylene glycol (PEG) or encapsulate it within nanoparticles for sustained release. Such modifications are detailed in the Certificate of Analysis when present, indicating any changes that might affect its biological activity.



Overall, the KPV Peptide 5 mg product is a valuable tool for scientists exploring anti-inflammatory strategies. Its well-characterized purity, robust analytical documentation, and defined application scope make it suitable for controlled laboratory experiments aimed at understanding and potentially harnessing the therapeutic potential of this short peptide sequence.